Roche's new extended partnership with Cancer Genetics will expand molecular diagnostic cancer testing in the Caribbean and Central America as part of a three-year deal.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.
Big Pharma wants the U.S. to pull a big-gorilla act in India. With patents revoked and cheap generics foisted on them ahead of schedule--and more early copycats possibly on their way--multinational drugmakers are lobbying for an intervention.
Australian CRO Novotech is heading west with its global expansion effort, opening up shop in South Africa to broaden its access to diverse patient populations.
The healthcare burdens of aging populations have traditionally been a Western problem, but rising life expectancy in emerging markets has caused the pressures to spread around the world. In India, the co-founder of IT services firm Infosys has responded by funding a brain and computing research center to improve the health of the 100 million citizens aged over 60.
Abbott Laboratories is cutting jobs, with plans to whack a plant in Puerto Rico as well as laying off staff at its Chicago-area headquarters. The company just won't say how many jobs are on the chopping block.
AstraZeneca is pulling the plug on an Indian research shop as part of its ongoing R&D re-think, planning to shed another 168 jobs as it moves away from neglected diseases and focuses on spaces with higher growth potential.
OneBreath, a maker of low-cost ventilators founded by Stanford University engineers, pulled in 180 million rupees (almost $3 million) in a funding round that will help it expand in emerging markets such as India, Africa and Eastern Europe.